Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Founded in 2019, Genesis aim to pioneer state-of-the-art innovation in generative and predictive AI for small molecule drug discovery.

Key proprietary innovations within its Genesis Exploration of Molecular Space (GEMS) AI platform include Dynamic PotentialNet and molecular generation engine. Dynamic PotentialNet integrates deep learning and molecular simulations to enable field-leading prediction of potency, selectivity, and ADMET. Molecular generation engine allows Genesis scientists to search immense swaths of chemical space and offers significant advantages in addressing challenging and previously undruggable targets.

The company is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego.